Lund, Sweden, March 23, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the ongoing OPTIMIZE-1 clinical P ...

Lund, Sweden, January 19, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the initiation a sponsored research collabor ...

Lund, Sweden, January 18, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the on-going OPTIMIZE-1 clinica ...

Lund, Sweden, January 7, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that Søren Bregenholt, Chief Executive Office ...

Alligator Bioscience AB (publ)’s ("Alligator" or the “Company") rights issue has now been registered with the Swedish Companies ...

Lund, Sweden, December 16, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the on-going clinical Phase I ...

Lund, Sweden and Seattle Washington, December 15, 2021 – Alligator Bioscience AB (“Alligator”) and Aptevo Therapeutics (“Aptevo”) (NASDAQ: A ...

Alligator Bioscience AB (publ) ("Alligator" or the "Company") has completed the rights issue of ordinary shares (the "Ri ...

Alligator Bioscience AB (publ) ("Alligator" or the "Company") announces that the Company’s rights issue of shares (the “Righ ...